An evaluation of empagliflozin and it's applicability to hypertension as a therapeutic option.
Lakshini Y HeratVance B MatthewsAaron L MagnoMárcio Galindo KiuchiRevathy CarnagarinMarkus P SchlaichPublished in: Expert opinion on pharmacotherapy (2020)
T1D: type 1 diabetes; T2D: type 2 diabetes; SGLT2: sodium-glucose cotransporter 2; CVD: cardiovascular disease; SBP: systolic blood pressure; DBP: diastolic blood pressure; SNS: sympathetic nervous system; BP: blood pressure; CV: cardiovascular; ZDF: Zucker diabetic fatty; CKD: chronic kidney disease; FDA: Food and Drug Administration.
Keyphrases
- blood pressure
- type diabetes
- chronic kidney disease
- cardiovascular disease
- hypertensive patients
- heart rate
- drug administration
- glycemic control
- end stage renal disease
- blood glucose
- insulin resistance
- metabolic syndrome
- heart failure
- adipose tissue
- risk assessment
- cardiovascular events
- wound healing
- skeletal muscle